AdvisorNet Financial Inc Boosts Stake in Eli Lilly and Company (NYSE:LLY)

AdvisorNet Financial Inc lifted its position in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 4.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,916 shares of the company’s stock after acquiring an additional 151 shares during the quarter. AdvisorNet Financial Inc’s holdings in Eli Lilly and were worth $1,270,000 as of its most recent SEC filing.

Several other hedge funds have also modified their holdings of the company. Massmutual Trust Co. FSB ADV lifted its stake in Eli Lilly and by 3.6% in the 2nd quarter. Massmutual Trust Co. FSB ADV now owns 5,801 shares of the company’s stock valued at $1,881,000 after buying an additional 204 shares in the last quarter. McLean Asset Management Corp lifted its stake in Eli Lilly and by 4.6% in the 2nd quarter. McLean Asset Management Corp now owns 1,469 shares of the company’s stock worth $485,000 after purchasing an additional 64 shares in the last quarter. Centre Asset Management LLC acquired a new stake in shares of Eli Lilly and during the 2nd quarter worth approximately $2,905,000. Vigilant Capital Management LLC increased its holdings in shares of Eli Lilly and by 3.7% during the 2nd quarter. Vigilant Capital Management LLC now owns 3,931 shares of the company’s stock worth $1,275,000 after buying an additional 141 shares during the last quarter. Finally, Bard Financial Services Inc. increased its holdings in shares of Eli Lilly and by 3.0% during the 2nd quarter. Bard Financial Services Inc. now owns 4,340 shares of the company’s stock worth $1,407,000 after buying an additional 125 shares during the last quarter. 82.45% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Eli Lilly and

In other Eli Lilly and news, SVP Alonzo Weems sold 656 shares of Eli Lilly and stock in a transaction on Wednesday, August 10th. The shares were sold at an average price of $304.50, for a total value of $199,752.00. Following the transaction, the senior vice president now directly owns 8,136 shares in the company, valued at $2,477,412. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, major shareholder Lilly Endowment Inc sold 89,458 shares of the business’s stock in a transaction dated Thursday, July 28th. The shares were sold at an average price of $332.85, for a total transaction of $29,776,095.30. Following the transaction, the insider now directly owns 103,875,441 shares in the company, valued at $34,574,940,536.85. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Alonzo Weems sold 656 shares of the business’s stock in a transaction dated Wednesday, August 10th. The stock was sold at an average price of $304.50, for a total transaction of $199,752.00. Following the transaction, the senior vice president now owns 8,136 shares in the company, valued at $2,477,412. The disclosure for this sale can be found here. Over the last three months, insiders have sold 753,125 shares of company stock worth $242,744,201. 0.12% of the stock is owned by company insiders.

Eli Lilly and Price Performance

Eli Lilly and stock opened at $308.89 on Friday. The stock has a market cap of $293.50 billion, a P/E ratio of 49.26, a price-to-earnings-growth ratio of 2.00 and a beta of 0.38. The company has a fifty day simple moving average of $316.13 and a 200-day simple moving average of $303.22. Eli Lilly and Company has a 12-month low of $220.20 and a 12-month high of $335.33. The company has a current ratio of 1.10, a quick ratio of 0.85 and a debt-to-equity ratio of 1.70.

Eli Lilly and (NYSE:LLYGet Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.86 by ($0.61). The firm had revenue of $6.49 billion for the quarter, compared to analysts’ expectations of $6.85 billion. Eli Lilly and had a return on equity of 85.58% and a net margin of 19.58%. Eli Lilly and’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same period last year, the firm posted $1.87 earnings per share. Equities analysts expect that Eli Lilly and Company will post 7.97 EPS for the current fiscal year.

Eli Lilly and Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 9th. Shareholders of record on Monday, August 15th were paid a $0.98 dividend. The ex-dividend date was Friday, August 12th. This represents a $3.92 dividend on an annualized basis and a yield of 1.27%. Eli Lilly and’s dividend payout ratio is presently 62.52%.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on LLY shares. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and from $340.00 to $355.00 in a report on Wednesday, June 1st. BMO Capital Markets raised their price target on shares of Eli Lilly and from $369.00 to $396.00 and gave the stock an “outperform” rating in a report on Tuesday, September 6th. Citigroup raised their price target on shares of Eli Lilly and from $285.00 to $370.00 in a report on Thursday, August 25th. Barclays lifted their target price on shares of Eli Lilly and from $333.00 to $355.00 and gave the company an “overweight” rating in a report on Thursday, July 7th. Finally, Morgan Stanley lifted their target price on shares of Eli Lilly and from $395.00 to $412.00 and gave the company an “overweight” rating in a report on Wednesday, September 7th. Three investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $330.44.

Eli Lilly and Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLYGet Rating).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.